C83.39 Diffuse large B-cell lymphoma, extranodal and solid organ sites

Name of the Condition

• Diffuse Large B-Cell Lymphoma, Extranodal and Solid Organ Sites (ICD-10 Code: C83.39)

Summary

Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma that originates in B-cells, a type of white blood cell. It is characterized by rapidly growing tumors in lymph nodes or other lymphoid tissues. This code specifies involvement of extranodal sites (outside lymph nodes) or solid organs. DLBCL is one of the most common subtypes of non-Hodgkin lymphoma and can occur in various parts of the body.

Causes

The exact cause of DLBCL is not fully understood. It is believed to result from genetic mutations in B-cells, which may be triggered by factors such as previous infections (e.g., Epstein-Barr virus), immune system dysfunctions, or exposure to certain environmental agents. These mutations disrupt normal cell growth and division, leading to uncontrolled proliferation.

Risk Factors

• Advanced age (most common in older adults)
• Weakened immune system (e.g., from HIV, organ transplants, or immunosuppressive drugs)
• Family history of lymphoma
• Exposure to certain chemicals or radiation
• Chronic infections (e.g., hepatitis C)

Symptoms

• Swollen, painless lymph nodes (most often in the neck, armpit, or groin)
• Unexplained weight loss
• Fever
• Night sweats
• Fatigue
• Loss of appetite
• Shortness of breath or chest pain (if lymph nodes in the chest are affected)
• Abdominal pain or swelling (if organs like the liver or spleen are involved)
• Skin lesions or masses (if extranodal sites are affected)

Diagnosis

Diagnosis involves a combination of physical examination, imaging studies (e.g., CT scans, PET scans), and biopsy of the affected tissue. A pathologist examines the biopsy sample under a microscope to confirm the presence of large B-cells and rule out other lymphoma subtypes. Additional tests, such as flow cytometry or genetic analysis, may be performed to characterize the lymphoma and guide treatment.

Treatment Options

Treatment typically includes chemoimmunotherapy regimens, such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Radiation therapy may be used for localized disease. For relapsed or refractory cases, additional therapies like targeted agents or stem cell transplantation may be considered. Treatment plans are tailored to the patient's age, overall health, and lymphoma characteristics.

Prognosis and Follow-Up

Prognosis varies based on factors like age, stage, and response to treatment. Many patients achieve remission with standard therapy, but some may experience recurrence. Follow-up care includes regular monitoring with physical exams, imaging, and blood tests to detect relapse or complications. Long-term survivors may require ongoing surveillance for late effects of treatment.

Complications

• Recurrence of lymphoma
• Infection due to weakened immune system
• Organ damage from tumor growth or treatment
• Secondary cancers (e.g., from chemotherapy or radiation)
• Metabolic complications (e.g., tumor lysis syndrome)

Lifestyle & Prevention

• Maintain a healthy immune system through balanced nutrition and regular exercise.
• Avoid known environmental risk factors (e.g., excessive radiation exposure).
• Manage chronic infections (e.g., hepatitis C) with appropriate medical care.
• Stay up-to-date with vaccinations, as directed by a healthcare provider.

When to Seek Professional Help

Seek immediate medical attention for:

• Sudden, unexplained weight loss or fever.
• Rapidly enlarging lymph nodes or new masses.
• Severe fatigue or persistent night sweats.
• Difficulty breathing, swallowing, or other symptoms affecting vital functions.

Tips for Medical Coders

• Use C83.39 when documentation specifies extranodal or solid organ involvement (e.g., gastrointestinal tract, skin, or other non-lymph node sites).
• Ensure the site is clearly documented to differentiate from nodal or unspecified sites.
• Verify that the diagnosis aligns with pathological confirmation of diffuse large B-cell lymphoma.
• Avoid using this code for other lymphoma subtypes or unspecified cases.